Improvement in Metabolic Health Parameters at Week 48 After Switching From a Tenofovir Alafenamide–Based 3- or 4-Drug Regimen to the 2-Drug Regimen of Dolutegravir/Lamivudine: The TANGO Study. Journal of Acquired Immune Deficiency Syndromes, 87(2): 794-800.
This website uses cookies to improve your experience. We’ll assume you’re ok with this, but you can opt-out if you wish. [cookie_settings] [cookie_button]
